Purine nucleosides
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 3, 2007
Grant Date -
Nov 17, 2005
app pub date -
Oct 24, 2003
filing date -
Oct 25, 2002
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Disclosed are purine nucleoside compounds that are selective to A.sub.3 adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The compounds are shown by the following general formula (I), including isomers thereof: ##STR00001## wherein X is sulfur or oxygen; R.sub.1 is hydrogen, alkyl, benzyl, halobenzyl, or phenylalkyl; R.sub.2 is hydrogen, halogen, alkoxy, alkenyl, alkynyl, alkylthio, or thio; R.sub.3 and R.sub.3' are hydrogen, hydroxyalkyl, alkoxycarbonyl, or alkylaminocarbonyl, whereas R.sub.3 and R.sub.3' do not have identical substituents simultaneously; and R.sub.4 is hydrogen or alkyl. Also disclosed are a pharmaceutical composition comprising a compound of formula (I), an isomer, or its pharmacologically acceptable salt as an active ingredient and a method for preventing or treating various diseases, state, or condition, including asthma, inflammation, cerebral ischemia, heart diseases, and cancer.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully